211 related articles for article (PubMed ID: 10379966)
1. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.
Etzioni R; Legler JM; Feuer EJ; Merrill RM; Cronin KA; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1033-9. PubMed ID: 10379966
[TBL] [Abstract][Full Text] [Related]
2. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
[TBL] [Abstract][Full Text] [Related]
3. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
Kaur D; Ulloa-Pérez E; Gulati R; Etzioni R
Cancer; 2018 Apr; 124(8):1752-1759. PubMed ID: 29370459
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
6. Trends in prostate cancer mortality among black men and white men in the United States.
Chu KC; Tarone RE; Freeman HP
Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516
[TBL] [Abstract][Full Text] [Related]
7. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.
Feuer EJ; Merrill RM; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1025-32. PubMed ID: 10379965
[TBL] [Abstract][Full Text] [Related]
8. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the role of PSA screening in the US prostate cancer mortality decline.
Etzioni R; Tsodikov A; Mariotto A; Szabo A; Falcon S; Wegelin J; DiTommaso D; Karnofski K; Gulati R; Penson DF; Feuer E
Cancer Causes Control; 2008 Mar; 19(2):175-81. PubMed ID: 18027095
[TBL] [Abstract][Full Text] [Related]
10. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
12. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
17. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
[TBL] [Abstract][Full Text] [Related]
18. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
20. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
Howrey BT; Kuo YF; Lin YL; Goodwin JS
J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
